PathAI and Bristol Myers Squibb Extend Multi-Year Collaboration Agreement

“Given the insights generated from past collaborations, we have entered into a long-term collaboration with Bristol Myers Squibb to expand our use of machine learning models. We will build on our work using AI-based pathology in translational research and validate the use of this technology through clinical trials and diagnostic development. Our ultimate goal is to improve patient care through AI.”

Andy Beck, Co-founder and CEO, PathAI

Today Path AI announced the extension of a multi-year collaboration agreement with?Bristol Myers Squibb to drive the use of AI-powered pathology in translation research and clinical trials. This extended agreement will focus on key translational research in oncology, fibrosis, and immunology, with an overall goal to continue transitioning this work into clinical trials. Bristol Myers Squibb and PathAI will utilize AI pathology models with the potential to de-risk therapeutic development across the Bristol Myers Squibb’s pipeline by better identifying patient populations.

The companies plan to leverage these models to obtain key insights to help enhance patient segmentation in clinical trials across multiple disease indications. The companies are also collaborating on developing AI-powered diagnostics, most notably measuring CD8 T-cell infiltration across oncology disease areas. This powerful biomarker has demonstrated the potential to predict response to immunotherapy and possibly inform patient treatment decisions.??

Bristol Myers Squibb is one of the world's largest pharma companies and manufactures medicines for cancer,?HIV,?cardiovascular disease,?diabetes,?hepatitis,?rheumatoid arthritis, and?psychiatric disorders. The company is using exploratory biomarker analyses to understand disease, disease variability, and mechanisms of drugs to identify which patients are most likely to benefit from specific medicines. The company has established the infrastructure to handle, process, and analyze digital images and is driving the development of cutting-edge AI-based techniques for automated image analysis.

“We look forward to collaborating with PathAI to expand the potential application of AI in the drug development process to include translational research, clinical trials and diagnostic advancements. We feel that PathAI will be a productive collaborator given digital pathology represents a growing area for BMS, PathAI is a leader in the field, and the fact that we have a long-standing productive relationship with the company.”??

Robert Plenge, M.D., Ph.D., Bristol Myers Squibb Senior Vice President and Head, Immunology, Cardiovascular and Fibrosis Thematic Research Center and Head, Translational Medicine

By partnering with biopharma companies PathAI leverages machine learning and deep learning to improve accuracy of diagnosis and the efficacy of treatment of serious diseases. The company's technology fuels biopharma initiatives from translational research through in vitro diagnostic device development to deliver faster, more accurate diagnoses and better personalized treatment plans for each patient.

Today’s announcement builds on the existing relationship between PathAI and Bristol Myers Squibb that began in 2016 and has shown results in multiple areas.

• In June 2020 PathAI and Bristol Myers Squibb presented retrospective exploratory findings from completed clinical trials on AI-powered PD-L1 scoring, which identified more patients as PD-L1 positive compared to manual-based PD-L1 scoring.?
• In November 2021 PathAI and Bristol Myers Squibb jointly presented results from PathAI’s CD8 algorithm at The Society for Immunotherapy of Cancer (SITC) Annual Meeting.
• In July 2022 PathAI and Bristol Myers Squibb jointly published new exploratory data in the Journal of Modern Pathology, comparing the use of AI-powered algorithms to manual IHC scoring PD-L1 expression in relation to outcomes across multiple cancer types from several clinical trials.

PathAI Announcements in 2022

• On August 12, 2022 PathAI announced that the company received clearance from both the FDA and the EU for their?AISight Dx?digital pathology platform for primary diagnosis in clinical settings. These designations are an important milestone and pave the way for in vitro diagnostics use of?AISight Dx with the Philips Ultra Fast Scanner in the US and the EU.
• On April 5, 2022 PathAI and?GlaxoSmithKline announced a strategic multi-year partnership to accelerate scientific research and drug development programs. The collaboration focuses on oncology and non-alcoholic steatohepatitis (NASH) by leveraging PathAI’s technologies in digital pathology including the use of PathAI’s AIM-NASH tool.
• On March 25, 2022, Roche announced a collaboration with Bristol Myers Squibb . As part of the collaboration the companies will integrate a novel algorithm developed by PathAI to analyze clinical trial samples and generate biomarker data.?AI will enable very precise diagnoses that will lead to personalized treatment options for patients with solid tumors.
• On March 15, 2022, PathAI and Cleveland Clinic announced a 5 year strategic collaboration. The partnership combines PathAI’s AI-based platforms with Cleveland Clinic’s clinical expertise and multi-modal data to unlock a broad implementation of next-generation pathology diagnostics. Cleveland Clinic will leverage PathAI’s quantitative pathology algorithms to conduct new translational research and for use as clinical diagnostics in multiple disease areas.

Subscribe and Comment

I'm interested in your feedback - please leave your comments. To subscribe please click subscribe at the top of this article.

Copyright ? 2022 Margaretta Colangelo. All Rights Reserved.

This article was written by?Margaretta Colangelo. ?Margaretta is Co-founder of Jthereum. She serves on the advisory board of the AI Precision Health Institute at the University of Hawai?i?Cancer Center. She's based in San Francisco?

Twitter?@realmargaretta